Clinical Trial

Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 21, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2018-08-24; most recent amendment 2025-08-15.
Trial Details
NCT Number NCT03648814
Lead Sponsor Prince of Songkla University
Conditions Glaucoma, Neovascular, Vascular Endothelial Growth Factor Overexpression
Enrollment 40 participants
Start Date 2018-08-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-21